keyword
MENU ▼
Read by QxMD icon Read
search

graft versus host disease prevention prophylaxis

keyword
https://www.readbyqxmd.com/read/29702996/phase-i-study-of-cord-blood-transplantation-with-intrabone-marrow-injection-of-mesenchymal-stem-cells-a-clinical-study-protocol
#1
Tatsunori Goto, Makoto Murata, Seitaro Terakura, Tetsuya Nishida, Yoshiya Adachi, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Fumihiko Hayakawa, Nobuhiro Nishio, Satoshi Nishiwaki, Akihiro Hirakawa, Katsuyoshi Kato, Yoshiyuki Takahashi, Hitoshi Kiyoi
INTRODUCTION: Delayed hematological recovery, graft failure, and acute graft-versus-host disease (GVHD) still remain major problems in cord blood transplantation (CBT). Mesenchymal stem cells (MSCs) are known to support bone marrow stroma and promote hematopoiesis. Additionally, MSCs possess immunomodulatory properties and are used clinically for the treatment of acute GVHD. Therefore, the use of MSCs to enhance engraftment and prevent GVHD after allogeneic hematopoietic cell transplantation has been explored...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29653205/varicella-zoster-virus-reactivation-in-adult-survivors-of-hematopoietic-cell-transplantation-how-do-we-best-protect-our-patients
#2
REVIEW
Catherine J Lee, Bipin N Savani, Per Ljungman
Reactivation of varicella zoster virus (VZV) remains a significant public health burden for long-term survivors of hematopoietic cell transplantation. Delayed immune reconstitution after transplantation due to immunosuppression, post-transplant therapies, poor engraftment, and graft-versus-host disease leave a large number of patients at risk for herpes zoster (shingles) and its highly morbid complications. Although prophylaxis with acyclovir or valacyclovir has reduced the incidence of VZV reactivation as long as prophylaxis is continued, the incidence of disease in the late post-transplant period or after stopping prophylaxis is greater in the hematopoietic cell transplantation population than the general public...
April 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29619911/early-use-of-etanercept-for-graft-versus-host-disease-after-liver-transplant-the-importance-of-broad-spectrum-infective-prophylaxis
#3
Annalisa Boscolo, Eugenia Menin, Beatrice Zelaschi, Laura Albertoni, Giacomo Zanus, Fabio Baratto
Graft-versus-host-disease after orthotopic liver transplant is a rare and life-threatening complication. The diagnosis is challenging and usually confirmed by chimerism and skin biopsies. The most common cause of death is sepsis (60%), and broad-spectrum antibiotics and antifungal prophylaxis are strongly recommended. We present a case of a 61-year-old man with hepatocellular carcinoma and a previous history of metabolic and alcoholic cirrhosis who underwent orthotopic liver transplant. The immunosuppression regimen consisted of corticosteroids, calcineurin inhibitor, and mammalian target of rapamycin complex 1 inhibitor...
April 4, 2018: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29530767/epstein-barr-virus-related-post-transplantation-lymphoproliferative-disorders-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
REVIEW
Li Liu, Xuyan Zhang, Sizhou Feng
Epstein-Barr virus (EBV)-related post-transplantation lymphoproliferative disorders (EBV-PTLDs) are rare but potentially fatal complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by uncontrolled proliferation of EBV-infected lymphocytes. The most common risk factors include T cell depletion of graft, HLA mismatch, severe graft-versus-host disease (GVHD), and EBV seromismatch (recipient-negative/donor-positive), among others. EBV-PTLDs commonly manifest as fever and lymphadenopathy and may rapidly progress to multiorgan failure and even death...
March 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29512935/cytomegalovirus-infections-in-lung-and-hematopoietic-cell-transplant-recipients-in-the-organ-transplant-infection-prevention-and-detection-study-a-multi-year-multicenter-prospective-cohort-study
#5
Robin K Avery, Fernanda P Silveira, Kaitlin Benedict, Angela A Cleveland, Carol A Kauffman, Mindy G Schuster, Erik R Dubberke, Shahid Husain, David L Paterson, Tom Chiller, Peter Pappas
BACKGROUND: Most studies of post-transplant CMV infection have focused on either solid organ or hematopoietic cell transplant (HCT) recipients. A large prospective cohort study involving both lung and HCT recipients provided an opportunity to compare the epidemiology and outcomes of CMV infections in these 2 groups. METHODS: Patients were followed up for 30 months in a 6-center prospective cohort study. Data on demographics, CMV infections, tissue-invasive disease, recurrences, rejection, and immunosuppression were recorded...
March 7, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29464765/delay-of-alternative-antiviral-therapy-and-poor-outcomes-of-acyclovir-resistant-herpes-simplex-virus-infections-in-recipients-of-allogeneic-stem-cell-transplant-a-retrospective-study
#6
Ella J Ariza-Heredia, Roy F Chemaly, Lokesh R Shahani, Ying Jang, Richard E Champlin, Victor E Mulanovich
Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyclovir-resistant HSV by plaque reduction test who received an HCT from 2002 through 2014. A total of 4 028 HCTs were performed during the study period, and 18 of the recipients met the diagnostic criteria for acyclovir-resistant HSV...
June 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/29454651/effects-of-prophylactic-foscarnet-on-human-herpesvirus-6-reactivation-and-encephalitis-in-cord-blood-transplant-recipients-a-prospective-multicenter-trial-with-an-historical-control-group
#7
Masao Ogata, Kuniko Takano, Yukiyoshi Moriuchi, Tadakazu Kondo, Toshimitsu Ueki, Nobuaki Nakano, Takehiko Mori, Nobuhiko Uoshima, Koji Nagafuji, Satoshi Yamasaki, Yasuhiko Shibasaki, Rika Sakai, Koji Kato, Ilseung Choi, Yumi Jo, Tetsuya Eto, Shinichi Kako, Kumi Oshima, Takahiro Fukuda
Cord blood transplantation (CBT) is a distinct risk factor for human herpesvirus-6 (HHV-6) reactivation and HHV-6 encephalitis. In a prospective multicenter trial we investigated the effects of prophylactic foscarnet (90 mg/kg i.v. infusion from days 7 to 27 after CBT) on the occurrence of HHV-6 reactivation, HHV-6 encephalitis, and acute graft-versus-host disease (aGVHD) in CBT recipients. Between 2014 and 2016, 57 patients were included in a foscarnet-prophylaxis group. Outcomes were compared with an historical control group who received CBT between 2010 and 2014 (standard-treatment group, n = 63)...
February 15, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29427741/pharmacokinetic-and-pharmacodynamic-markers-of-mycophenolic-acid-associated-with-effective-prophylaxis-for-acute-graft-versus-host-disease-and-neutrophil-engraftment-in-cord-blood-transplant-patients
#8
Kazuaki Yoshimura, Ikuko Yano, Takashi Yamamoto, Tadakazu Kondo, Misaki Kawanishi, Yui Isomoto, Atsushi Yonezawa, Akifumi Takaori-Kondo, Kazuo Matsubara
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA) and is frequently used to prevent acute graft-versus-host disease (aGVHD) in patients receiving hematopoietic stem cell transplantation (HSCT). However, optimal doses of MMF and target MPA concentrations in HSCT patients have not been defined. In this study, relationships between pharmacokinetic or pharmacodynamic markers of MPA and successful aGVHD prevention and neutrophil engraftment were evaluated to inform individualized MPA treatments in HSCT patients...
February 7, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29412158/allogeneic-hematopoietic-stem-cell-transplantation-for-gata2-deficiency-using-a-busulfan-based-regimen
#9
Mark Parta, Nirali N Shah, Kristin Baird, Hind Rafei, Katherine R Calvo, Thomas Hughes, Kristen Cole, Meg Kenyon, Bazetta Blacklock Schuver, Jennifer Cuellar-Rodriguez, Christa S Zerbe, Steven M Holland, Dennis D Hickstein
Allogeneic hematopoietic stem cell transplantation (HSCT) reverses the bone marrow failure syndrome due to GATA2 deficiency. The intensity of conditioning required to achieve reliable engraftment and prevent relapse remains unclear. Here, we describe the results of a prospective study of HSCT in 22 patients with GATA2 deficiency using a busulfan-based conditioning regimen. The study included 2 matched related donor (MRD) recipients, 13 matched unrelated donor (URD) recipients, and 7 haploidentical related donor (HRD) recipients...
February 3, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29407317/graft-versus-host-disease-free-relapse-free-survival-after-hla-identical-sibling-peripheral-blood-stem-cell-transplantation-with-tacrolimus-based-graft-versus-host-disease-prophylaxis-in-japanese-patients
#10
S Shingaki, N Tsukada, M Ikeda, K Suzuki
The ideal post-allogeneic hematopoietic cell transplantation recovery is not just the cure of hematologic malignancies but also freedom from ongoing morbidity. Recent studies have revealed that HLA-identical sibling peripheral blood stem cell transplantation (PBSCT) had been providing impaired graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) due to a higher risk of GVHD. Study on GVHD prophylaxis bears clinical reliance when focused on Japanese population because risk of GVHD differs among races...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29351985/tocilizumab-tacrolimus-and-methotrexate-for-the-prevention-of-acute-graft-versus-host-disease-low-incidence-of-lower-gastrointestinal-tract-disease
#11
William R Drobyski, Aniko Szabo, Fenlu Zhu, Carolyn Keever-Taylor, Kyle M Hebert, Renee Dunn, Sharon Yim, Bryon Johnson, Anita D'Souza, Mary Eapen, Timothy S Fenske, Parameswaran Hari, Mehdi Hamadani, Mary M Horowitz, J Douglas Rizzo, Wael Saber, Nirav Shah, Bronwen Shaw, Marcelo Pasquini
We conducted a phase 2 study in which patients undergoing allogeneic hematopoietic stem cell transplantation received tocilizumab in addition to standard immune suppression with tacrolimus and methotrexate for graft- versus -host disease prophylaxis. Thirty-five patients were enrolled between January 2015 and June 2016. The median age of the cohort was 66 (range: 22-76). All patients received busulfan-based conditioning, and were transplanted with human leukocyte antigen-matched related or matched unrelated bone marrow or peripheral stem cell grafts...
April 2018: Haematologica
https://www.readbyqxmd.com/read/29325830/blood-and-marrow-transplant-clinical-trials-network-report-on-the-development-of-novel-endpoints-and-selection-of-promising-approaches-for-graft-versus-host-disease-prevention-trials
#12
Marcelo C Pasquini, Brent Logan, Richard J Jones, Amin M Alousi, Frederick R Appelbaum, Javier Bolaños-Meade, Mary E D Flowers, Sergio Giralt, Mary M Horowitz, David Jacobsohn, John Koreth, John E Levine, Leo Luznik, Richard Maziarz, Adam Mendizabal, Steven Pavletic, Miguel-Angel Perales, David Porter, Ran Reshef, Daniel Weisdorf, Joseph H Antin
Graft-versus-host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here we report a benchmark analysis to evaluate the performance of 6 GVHD prevention strategies tested at single institutions compared with a large multicenter outcomes database as a control. Each intervention was compared with the control for the incidence of acute and chronic GVHD and overall survival and against novel composite endpoints: acute and chronic GVHD, relapse-free survival (GRFS), and chronic GVHD, relapse-free survival (CRFS)...
June 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29197677/distinct-biomarker-profiles-in-ex-vivo-t-cell-depletion-graft-manipulation-strategies-cd34-selection-versus-cd3-19-depletion-in-matched-sibling-allogeneic-peripheral-blood-stem-cell-transplantation
#13
Caroline R Cantilena, Sawa Ito, Xin Tian, Prachi Jain, Fariba Chinian, Prathima Anandi, Keyvan Keyvanfar, Debbie Draper, Eleftheria Koklanaris, Sara Hauffe, Jeanine Superata, David Stroncek, Pawel Muranski, A John Barrett, Minoo Battiwalla
Various approaches have been developed for ex vivo T cell depletion in allogeneic stem cell transplantation to prevent graft-versus-host disease (GVHD). Direct comparisons of T cell depletion strategies have not been well studied, however. We evaluated cellular and plasma biomarkers in 2 different graft manipulation strategies, CD3+ CD19+ cell depletion (CD3/19D) versus CD34+ selection (CD34S), and their associations with clinical outcomes. Identical conditions, including the myeloablative preparative regimen, HLA-identical sibling donor, GVHD prophylaxis, and graft source, were used in the 2 cohorts...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29112242/a-randomized-study-of-cyclosporine-and-methotrexate-with-or-without-methylprednisolone-for-the-prevention-of-graft-versus-host-disease-improved-long-term-survival-with-triple-prophylaxis
#14
Tapani Ruutu, Anne Nihtinen, Riitta Niittyvuopio, Eeva Juvonen, Liisa Volin
BACKGROUND: In a previously published study, the authors randomized 108 adult patients with a malignant hematologic disorder undergoing allogeneic bone marrow transplantation from a human leukocyte antigen-identical sibling to receive methylprednisolone (53 patients; MP+) or not to receive methylprednisolone (55 patients; MP-) as a part of graft-versus-host disease (GVHD) prophylaxis. All patients received cyclosporine and methotrexate. The cumulative incidence of acute GVHD was found to be significantly lower among the patients given MP...
February 15, 2018: Cancer
https://www.readbyqxmd.com/read/29100905/post-transplant-cyclophosphamide-as-sole-graft-versus-host-disease-prophylaxis-is-feasible-in-patients-undergoing-peripheral-blood-stem-cell-transplantation-for-severe-aplastic-anemia-using-matched-sibling-donors
#15
Biju George, Nisham Pn, Anup J Devasia, Uday Kulkarni, Anu Korula, Kavitha M Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews
High-dose cyclophosphamide (PTCY) after allogeneic hematopoietic cell transplantation (HSCT) has been shown to be effective in preventing graft-versus-host disease (GVHD) after HLA-matched bone marrow transplantation. We performed a phase II study of PTCY given at 50 mg/kg i.v. on days 3 and 4 as the sole GVHD prophylaxis after HSCT for severe aplastic anemia (SAA) in patients receiving granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts from HLA-matched related donors after conditioning with fludarabine, CY, and single-dose total body irradiation...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29061535/pharmacodynamic-monitoring-predicts-outcomes-of-ccr5-blockade-as-graft-versus-host-disease-prophylaxis
#16
Austin P Huffman, Lee P Richman, Lisa Crisalli, Alex Ganetsky, David L Porter, Robert H Vonderheide, Ran Reshef
Blocking lymphocyte trafficking after allogeneic hematopoietic stem cell transplantation is a promising strategy to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-tumor response. Maraviroc, a CCR5 antagonist, has shown promise in clinical trials, presumably by disrupting the migration of effector cells to GVHD target organs. We describe a phosphoflow assay to quantify CCR5 blockade during treatment with maraviroc and used it to evaluate 28 patients in a phase II study. We found that insufficient blockade of CCR5 was associated with significantly worse overall survival (HR, 10...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29037136/effect-of-priming-of-multipotent-mesenchymal-stromal-cells-with-interferon-%C3%AE-on-their-immunomodulating-properties
#17
N M Kapranov, Y O Davydova, I V Galtseva, N A Petinati, N I Drize, L A Kuzmina, E N Parovichnikova, V G Savchenko
Multipotent mesenchymal stromal cells (MSCs) are widely used for cell therapy, in particular for prophylaxis and treatment of graft-versus-host disease. Due to their immunomodulatory properties, MSCs affect the composition of lymphocyte subpopulations, which depends on the immunological state of the organism and can change in different diseases and during treatment. Administration of MSCs is not always effective. Treatment of MSCs with different cytokines (in particular IFN-γ) leads to enhancement of their immunomodulatory properties...
October 2017: Biochemistry. Biokhimii︠a︡
https://www.readbyqxmd.com/read/28978855/allogeneic-hematopoietic-stem-cell-transplantation-using-atg-prophylaxis-and-treatment
#18
Nobuhiro Nishio, Yoshiyuki Takahashi, Seiji Kojima
Graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation is associated with an increase in patient transplant-related morbidity and mortality and a decrease in quality of life. Adequate immune suppression is critical to prevent GVHD without increasing the risk of developing a severe infection or relapse of malignancy. Anti-T cell globulin (ATG) combined with other immunosuppressive drugs can reduce the risk of severe acute GVHD and extensive chronic GVHD without enhancing the rate of severe infection or relapse of malignancy...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28846051/in-vivo-or-ex-vivo-t-cell-depletion-or-both-to-prevent-graft-versus-host-disease-after-hematopoietic-stem-cell-transplantation
#19
REVIEW
Alessandro Busca, Franco Aversa
Hematopoietic stem cell transplantation (HSCT) represents a widely accepted therapeutic strategy for the treatment of hematologic disorders which are otherwise considered incurable. Alloreactive T cells infused with the stem cell inoculum may generate graft-versus-host disease (GVHD) representing one the most relevant obstacles to the successful outcome of patients receiving allogeneic HSCT. Areas covered: In this review, the authors provide an overview of the most recent approaches of T-cell depletion (TCD) including ex-vivo αβ+ TCD and in-vivo TCD with anti-thymocyte globulin (ATG)...
November 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28840382/new-photobiomodulation-protocol-prevents-oral-mucositis-in-hematopoietic-stem-cell-transplantation-recipients-a-retrospective-study
#20
Camila Weissheimer, Marina Curra, Lauro J Gregianin, Liane E Daudt, Vivian P Wagner, Marco Antonio T Martins, Manoela D Martins
Oral mucositis (OM) is an adverse side effect among hematopoietic stem cell transplantation (HSCT) recipients. The objective of this retrospective study was to evaluate the preventive effect of photobiomodulation (PBM) applied three times per week versus seven times per week in patients undergoing HSCT. The risk factors related to the incidence and severity of OM were also assessed. This was a retrospective study that evaluated 99 HSCT recipients who received different PBM protocols. Group I received three sessions per week, and group II received daily treatment...
December 2017: Lasers in Medical Science
keyword
keyword
78151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"